Current literature describes symptom improvement in roughly 60–75% of trial participants, though definitions of 'improvement' vary widely and placebo response rates in menopausal symptom trials historically exceed 40%. No head-to-head trials against hormone therapy exist. Real-world outcomes beyond trial settings remain unreported. The wide range reflects heterogeneous populations and measurement methods rather than robust efficacy.
Approximately 10 registered trials are investigating stem cell and exosome therapies for menopause-related symptoms. A 2023 small-scale study of placental MSCs reported subjective improvement in hot flush frequency in 70% of participants over 12 weeks, though follow-up assessments remain limited. Exosome trials have focused on anti-inflammatory signalling rather than direct hormone replacement. No large multicentre randomised controlled trials have yet demonstrated safety or efficacy comparable to hormone therapy, and recruitment for new menopause-focused stem cell studies has stalled. Evidence remains preliminary and largely mechanistic.
האם אני מועמד? → · Menopause & Hormonal Health: full overview → · עלות גיל התחלופה ובריאות הורמונלית → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם